YM Biosciences Inc (YM)

Currency in CAD
0.000
0.000(0.00%)
Closed·
Showing YM Biosciences Inc historical data. For real-time data please try another search
Day's Range
0.0000.000
52 wk Range
0.0000.000
Key Statistics
Prev. Close
-
Open
-
Day's Range
-
52 wk Range
0-0
Volume
-
Average Volume (3m)
42.92K
1-Year Change
84.38%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

YM Biosciences Inc Company Profile

YM BioSciences Inc., a drug development company, engages in developing hematology and cancer-related products. Its products include CYT387, a dual inhibitor of the JAK1 and JAK2 kinases, which has implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, as well in various other disorders comprising indications in hematology, oncology, and inflammatory diseases. The company is evaluating, CYT387, in a Phase I/II trial and a Phase II trial for the treatment of patients with myelofibrosis, a chronic debilitating disease in which a patient’s bone marrow is replaced by scar tissue. It is also developing nimotuzumab, a humanized monoclonal antibody, which is in various Phase II and III trials worldwide targeting epidermal growth factor receptor antibody. In addition, the company has various preclinical research programs underway with candidates from its library of compounds. YM BioSciences Inc. has collaboration agreements with Daiichi-Sankyo Pharmaceutical Co. Ltd., Kuhnil Pharmaceutical Company, Innogene Kalbiotech, Oncoscience AG, the Center of Molecular Immunology, Pulmokine Inc, and Cancer Therapeutics CRC Pty Ltd. The company was formerly known as York Medical Inc. and changed its name to YM Biosciences Inc. in February 2001. YM BioSciences Inc. was founded in 1994 and is headquartered in Mississauga, Canada. As of February 8, 2013, YM BioSciences Inc. operates as a subsidiary of Gilead Sciences Inc.

Earnings

Latest Release
Feb 07, 2013
EPS / Forecast
-0.07 / --
Revenue / Forecast
3.86M / --
EPS Revisions
Last 90 days

YM Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.